

MSF Scientific Days International (London) Medical Research Day (13th May)

Agenda 2020

Introduction and Welcome – Melissa McRae, Medical Director, MSF Operational Centre Amsterdam

1010 - 1135 Session 1 – Challenges to Trace, Track and Treat
Session Chair – Dr Sabine Dittrich

1. [Incidence of relapse at three months in young children who recovered under the OptiMA strategy for management of acute malnutrition: prospective cohort, Burkina Faso](#)
Kevin Phelan, The Alliance for International Medical Action (ALIMA), Paris, France
2. [Identifying high-risk villages to screen for human African trypanosomiasis in Maniema, Democratic Republic of Congo: findings from an active screening campaign](#)
Paul Boko, Médecins Sans Frontières (MSF), Bukavu, Democratic Republic of the Congo (DRC)
Tom Woudenberg, MSF, Amsterdam, The Netherlands
3. [Diagnosing and treating cases of acute HIV infection within a high HIV incidence setting: feasibility study, Eswatini](#)
Aung Aung, Médecins Sans Frontières (MSF), Nhlangano, Eswatini
4. [Improving access to care for survivors of sexual violence: key lessons from two mixed-methods studies, Haiti and India](#)
Meggy Verputten, Médecins Sans Frontières (MSF), Amsterdam, The Netherlands

1205 - 1310 Session 2 – Keynote: The Storm and the Flood: Humanitarian Responsibilities and COVID-19

Session Participants:

Sean Healy, Head of Research and Analysis, MSF Operational Centre Amsterdam

Dr Paul Spiegel, Director, Centre for Humanitarian Health, John Hopkins Bloomberg School of Public Health

Dr Maysoon Dahab, Senior Research Associate, Conflict and Health Programme, King's College London

1340 - 1500 Session 3 – Evolving Thinking: Adapting Programming
Session Chair – Philipp Du Cros

1. [Ensuring the difference between life and death”: MSF’s experience with differentiated models of HIV care during conflict, Zemi, Central African Republic](#)
Charles Ssonko and Nell Gray, Médecins Sans Frontières (MSF), London, UK
2. [Person-centred care in practice: perspectives from a short-course regimen for multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan: qualitative study](#)
Shona Horter, Médecins Sans Frontières (MSF), London, UK

3. [Lived experiences and perceptions of palliative care among advanced HIV patients: qualitative study, Bihar, India](#)
Mohit Nair, *Médecins Sans Frontières (MSF), New Delhi, India*
4. [Safety and efficacy data from a phase 2 randomized trial of a miltefosine/thermotherapy combination in uncomplicated New World cutaneous leishmaniasis](#)
Byron Arana, *Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland*

1530 - 1650

Session 4 – Conflict, Complexity, Compliance: Challenges in Prevention
Session Chair - Dr Susan Shepherd

1. [Use of population pharmacokinetics to assess adherence to amodiaquine used for seasonal malaria chemoprevention](#)
Matthew E. Coldiron, *Epicentre, Paris, France*
2. [Measles deaths in the current Democratic Republic of Congo epidemic: estimates from four population-based surveys](#)
Etienne Gignoux, *Epicentre, Paris, France*
3. [Validation of GeneXpert testing for human papillomavirus and self-collected sampling for cervical cancer screening in Gutu District, Zimbabwe](#)
Yuster Ronoh, *Médecins Sans Frontières (MSF), Harare, Zimbabwe*
4. [Hypertension management in MSF programmes in Jordan and Zimbabwe: opportunities for simplification and use of fixed-dose combination medications](#)
Helen Bygrave, *Médecins Sans Frontières (MSF), London, UK*

1650 – 1700 Closing Remarks – **Kiran Jobanputra**, *Head of the Manson Unit, MSF UK, and Deputy Medical Director, MSF Operational Centre Amsterdam*